ADMA Q3 2018 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-10.6% YoY

Gross Profit

-$5M-116.6% margin

Operating Income

-$14M-326.0% margin

Net Income

-$15M-357.8% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-9.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$577,581

Balance Sheet

Total Assets

$106M

Total Liabilities

$69M

Stockholders' Equity

$37M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-10.6%
Gross Profit	-$5M	-$7M	+24.8%
Operating Income	-$14M	-$14M	+4.4%
Net Income	-$15M	-$15M	+0.4%